GenSight Biologics SA (SIGHT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
64
About the Report
About the Report
Summary
GenSight Biologics SA (GenSight) is a clinical stage biotechnology company that discovers and develops novel therapies for mitochondrial and neurodegenerative diseases. The company's product pipeline comprises GS010 and GS030 developed for the treatment of retinal degenerative diseases. It develops solutions for preserving or restoring vision in patients suffering from very low vision or blindness due to degenerative retinal and inherited ophthalmologic diseases. GenSight's drugs target against gene replacement therapy for vision loss in leber hereditary optic neuropathy. It also develops products for retinitis pigmentosa and other hereditary diseases of retina. GenSight is headquartered in Paris, France.
GenSight Biologics SA (SIGHT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
GenSight Biologics SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenSight Biologics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018 10
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
GenSight Biologics Raises USD 41.6 Million In Series A Financing 13
Partnerships 15
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 15
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 16
GenSight Biologics Enters into Research Agreement with Friedrich Miescher Institute 17
GenSight Biologics Enters into Agreement with Genethon 18
Licensing Agreements 19
Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 19
GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 20
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 22
GenSight Biologics Enters into Licensing Agreement with Novartis Pharma 24
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 25
Equity Offering 27
Gensight Biologics Raises USD25 Million in Private Placement of Shares 27
GenSight Biologics Announces Underwriters Exercise of Partial Over-Allotment Option for IPO of Shares for USD50.5 Million 28
GenSight Biologics Raises USD35.3 Million in Private Placement of Series B Preferred Stock 30
GenSight Biologics SA-Key Competitors 32
GenSight Biologics SA-Key Employees 33
GenSight Biologics SA-Locations And Subsidiaries 34
Head Office 34
Recent Developments 35
Financial Announcements 35
Jul 25, 2018: GenSight Biologics Reports Interim Financial Results for the First Half of 2018 35
Jan 25, 2018: GenSight Biologics Reports EUR55 Million 2017 Year-End Cash Position and Provides Corporate Update 36
Jul 28, 2017: GenSight Biologics Reports Interim Financial Results for the First Half of 2017 37
Apr 26, 2017: GenSight Biologics Reports Its Cash Position as of March 31, 2017 38
Mar 13, 2017: GenSight Biologics Reports Full Year 2016 Financial Results 39
Corporate Communications 40
Oct 25, 2017: GenSight Biologics Appoints Barrett Katz as Chief Medical Officer 40
Oct 02, 2017: GenSight Biologics Integrates the Enternext PEA-PME 150 Index 41
May 03, 2017: Gensight Biologics Appoints Mohamed Genead as Chief Medical Officer 42
Product News 43
10/16/2017: GenSight Biologics to Present Data on GS010 at 2017 Congress of the European Society of Gene & Cell Therapy 43
10/16/2017: GenSight Biologics to Present Data on GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy 44
06/14/2017: GenSight Biologics Reports Long-Term Positive Safety and Visual Acuity Results at Week 96 in Phase I/II Study of GS010 for the Treatment of Leber's Hereditary Optic Neuropathy 45
05/08/2017: GenSight Biologics to Present Data on GS030 at the Annual Meeting of ARVO 46
Product Approvals 47
Jan 31, 2017: GenSight Biologics Receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa 47
Clinical Trials 48
Jun 20, 2018: GenSight Biologics : Key Opinion Leaders Highlight GS010 Efficacy and Patient Benefits in Discussion of Findings from REVERSE Phase III Clinical Trial 48
Jun 12, 2018: GenSight Biologics Reports Positive Additional Data from REVERSE Phase III Clinical Trial of GS010 for Treatment of Leber Hereditary Optic Neuropathy (LHON) 50
Apr 26, 2018: GenSight Biologics to Present Data on GS010 at the Annual Meeting of Association for Research in Vision and Ophthalmology 52
Apr 03, 2018: GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON) 54
Feb 20, 2018: GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in Ophthalmology, the Journal of the American Academy of Ophthalmology 56
Dec 05, 2017: GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) 58
Aug 01, 2017: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the Treatment of Leber's Hereditary Optic Neuropathy 60
May 08, 2017: GenSight Biologics to Present Data on GS010 at the Annual Meeting of ARVO 61
Feb 21, 2017: GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber's Hereditary Optic Neuropathy 62
Other Significant Developments 63
Apr 25, 2018: GenSight Biologics reports EUR49 million cash position as of March 31, 2018 and provides update on GS010 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
List of Figure
List of Figures
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
GenSight Biologics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenSight Biologics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenSight Biologics SA, Deals By Therapy Area, 2012 to YTD 2018 9
GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018 10
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GenSight Biologics Raises USD 41.6 Million In Series A Financing 13
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 15
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 16
GenSight Biologics Enters into Research Agreement with Friedrich Miescher Institute 17
GenSight Biologics Enters into Agreement with Genethon 18
Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 19
GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 20
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 22
GenSight Biologics Enters into Licensing Agreement with Novartis Pharma 24
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 25
Gensight Biologics Raises USD25 Million in Private Placement of Shares 27
GenSight Biologics Announces Underwriters Exercise of Partial Over-Allotment Option for IPO of Shares for USD50.5 Million 28
GenSight Biologics Raises USD35.3 Million in Private Placement of Series B Preferred Stock 30
GenSight Biologics SA, Key Competitors 32
GenSight Biologics SA, Key Employees 33
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.